Results 21 to 30 of about 3,437 (189)

Quality by Design-Guided Development of Hydrogel-Forming Microneedles for Transdermal Delivery of Enfuvirtide. [PDF]

ACS Appl Mater Interfaces
Enfuvirtide, the inaugural biomimetic fusion inhibitor of HIV-1, has exhibited remarkable antiviral efficacy when administered in conjunction with an optimized antiretroviral regimen.
Li H, Vora LK, Anjani Q, Abraham AM, Cong Y, Moreno-Castellanos N, Ballana E, Riveira Muñoz E, Nevot M, Donnelly RF.   +9 more
europepmc   +2 more sources

The HR2 polymorphism N140I in the HIV-1 gp41 combined with the HR1 V38A mutation is associated with a less cytopathic phenotype

Retrovirology, 2012
Background Resistance to the fusion inhibitor enfuvirtide (ENF) is achieved by changes in the gp41 subunit of the HIV envelope glycoprotein (Env). Specific ENF-associated mutational pathways correlate with immunological recovery, even after virological ...
Cunyat Francesc, Marfil Silvia, García Elisabet, Svicher Valentina, Pérez-Alvárez Nuria, Curriu Marta, Perno Carlo, Clotet Bonaventura, Blanco Julià, Cabrera Cecilia   +9 more
doaj   +1 more source

Recent Developments in HIV Antivirals: The Prospect of Prophylactic Drugs to Change the Pandemic. [PDF]

Microb Biotechnol
Replication cycle of HIV‐1. The scheme provides an overview from virus entry over reverse transcription of viral RNA into viral DNA, provirus DNA integration into the host genome, genome expression by transcription and translation, proteolytic processing of the viral polyproteins, viral maturation to viral release from the cell. The various targets for
Brüssow H.
europepmc   +2 more sources

A novel class of anti-HIV agents with multiple copies of enfuvirtide enhances inhibition of viral replication and cellular transmission in vitro. [PDF]

PLoS ONE, 2012
We constructed novel HIV-1 fusion inhibitors that may overcome the current limitations of enfuvirtide, the first such therapeutic in this class. The three prototypes generated by the Dock-and-Lock (DNL) technology to comprise four copies of enfuvirtide ...
Chien-Hsing Chang, Jorma Hinkula, Meiyu Loo, Tina Falkeborn, Rongxiu Li, Thomas M Cardillo, Edmund A Rossi, David M Goldenberg, Britta Wahren   +8 more
doaj   +1 more source

Susceptibility of HIV-1 subtypes B', CRF07_BC and CRF01_AE that are predominantly circulating in China to HIV-1 entry inhibitors. [PDF]

PLoS ONE, 2011
The B', CRF07_BC and CRF01_AE are the predominant HIV-1 subtypes in China. It is essential to determine their baseline susceptibility to HIV entry inhibitors before these drugs are used in China.The baseline susceptibility of 14 representative HIV-1 ...
Xiaoling Yu, Lin Yuan, Yang Huang, Weisi Xu, Zhiming Fang, Shuwen Liu, Yiming Shao, Shibo Jiang, Liying Ma   +8 more
doaj   +1 more source

HIV-1 Non Group-M Phenotypic Susceptibility to Ibalizumab. [PDF]

J Med Virol
ABSTRACT The study assessed the phenotypic susceptibility of non group‐M human immunodeficiency virus type 1 (HIV‐1/non‐M) clinical isolates to ibalizumab, the first‐in‐class long‐acting CD4‐directed post‐attachment inhibitor. Thirty isolates were tested: 1 HIV‐1/M (reference strain BRU.HXB2), 2 HIV‐1/N, 26 HIV‐1/O and 1 HIV‐1/P.
Poisson L, Hingrat QL, Lermechain F, Tombette F, Jullien H, Plantier JC, Alessandri-Gradt E.   +6 more
europepmc   +2 more sources

A compensatory mutation provides resistance to disparate HIV fusion inhibitor peptides and enhances membrane fusion. [PDF]

PLoS ONE, 2013
Fusion inhibitors are a class of antiretroviral drugs used to prevent entry of HIV into host cells. Many of the fusion inhibitors being developed, including the drug enfuvirtide, are peptides designed to competitively inhibit the viral fusion protein ...
Matthew P Wood, Amy L Cole, Piotr Ruchala, Alan J Waring, Lisa C Rohan, Preston Marx, Patrick M Tarwater, Phalguni Gupta, Alexander M Cole   +8 more
doaj   +1 more source

HIV-1 inhibitory properties of eCD4-Igmim2 determined using an Env-mediated membrane fusion assay. [PDF]

PLoS ONE, 2018
Human Immunodeficiency Virus-1 (HIV-1) entry is dependent on the envelope glycoprotein (Env) that is present on the virion and facilitates fusion between the envelope and the cellular membrane.
Edward Yang, Matthew R Gardner, Amber S Zhou, Michael Farzan, Ann M Arvin, Stefan L Oliver   +5 more
doaj   +1 more source

Immunization with HIV-1 envelope T20-encoding DNA vaccines elicits cross-clade neutralizing antibody responses

Human Vaccines & Immunotherapeutics, 2017
Background: Genetic immunization is expected to induce the expression of antigens in a native form. The encoded peptide epitopes are presented on endogenous MHC molecules, mimicking antigen presentation during a viral infection.
S. Stenler, K. E. Lundin, L. Hansen, S. Petkov, N. Mozafari, M. Isaguliants, P. Blomberg, C. I. E. Smith, D. M. Goldenberg, C.-H. Chang, K. Ljungberg, J. Hinkula, B. Wahren   +12 more
doaj   +1 more source

Immunostimulatory effects on THP-1 cells by peptide or protein pharmaceuticals associated with injection site reactions

Journal of Immunotoxicology, 2020
Injection site reaction (ISR) is a common side-effect associated with the use of peptide or protein pharmaceuticals. These types of pharmaceuticals-induced activation of antigen-presenting cells is assumed to be a key step in the pathogenesis of immune ...
Eri Hamamura-Yasuno, Tetsuo Aida, Yoshimi Tsuchiya, Kazuhiko Mori   +3 more
doaj   +1 more source